Chokri Ben Lamine/LinkedIn
Jun 12, 2026, 16:14
Chokri Ben Lamine: EHA26 – SCD Curative Therapy Pathway
Chokri Ben Lamine, Assistant Consultant at King Faisal Specialist Hospital and Research Center, shared a post on X:
“EHA26 – SCD Curative Therapy Pathway
EHA-SWG and EBMT-HWP joint recommendations highlight who should be considered for:
- Allogeneic HCT
- Cell and gene therapy
in sickle cell disease
Key clinical logic:
- Confirm HbSS and severe HbSβ⁰ genotype
- Assess for severe clinical presentation
- If HLA-matched family donor is available, proceed to allo-HCT assessment
- If no matched donor is available and eligibility criteria are met, assess for gene therapy at a transplant center.
Practical message:
Curative therapy in SCD is becoming algorithm-driven, but still needs expert individualized review:
- genotype
- disease severity
- donor availability
- age
- regulatory and scientific updates
- patient-centered risk–benefit discussion
Session: Optimising the transplant process in haemoglobinopathies
Chair: Ben Carpenter”
Other posts featuring Chokri Ben Lamine on Hemostasis Today.
-
Sep 19, 2026, 14:17Abdul Mannan: What Exactly Is a Platelet?
-
Sep 19, 2026, 13:39Keisuke Goda: Decoding Platelet Phenotypes in COVID-19 With Optofluidic Imaging
-
Sep 19, 2026, 13:30Targeted Thrombolysis Beyond tPA
-
Sep 19, 2026, 13:21Paul Armstrong: From Summer Studentship to Young Researcher
-
Sep 19, 2026, 13:06Rabiya Masood: Breaking the Cycle of Thalassemia Through Screening
-
Sep 19, 2026, 10:52Consuela A. Albright: The Critical Role of Black Blood Donors in Sickle Cell Treatment
-
Sep 19, 2026, 10:47Amber Yates: Inside Agios’ Partnership with the Sickle Cell Community
-
Sep 19, 2026, 10:46Anton Farkas: Mechanical Thrombectomy for Acute PE in Early Pregnancy
-
Sep 19, 2026, 10:40Marjolein Smidt: ASH Raises Ferritin Thresholds for Iron Deficiency